# A Study of AK0529 to Evaluate Pharmacokinetics and Safety in Chinese Healthy Volunteers

> **NCT03322800** · PHASE1 · COMPLETED · sponsor: **Shanghai Ark Biopharmaceutical Co., Ltd.** · enrollment: 51 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** AK0529
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT03322800
- **Lead sponsor:** Shanghai Ark Biopharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-10-23
- **Primary completion:** 2018-04-06
- **Final completion:** 2018-05-24
- **Target enrollment:** 51 (ACTUAL)
- **Last updated:** 2021-06-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03322800

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03322800, "A Study of AK0529 to Evaluate Pharmacokinetics and Safety in Chinese Healthy Volunteers". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03322800. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*